Geron, a Menlo Park, California based developer of biopharmaceuticals for the treatment of cancer and chronic degenerative diseases by targeting the enzyme telomerase, added an ex-CMO of SPRI (the research arm of legacy Schering-Plough) to its board:
. . . .Geron Corporation today announced the appointment of Hoyoung Huh, M.D., Ph.D. and Robert J. Spiegel, M.D., FACP to its board of directors. . . .
After 26 years with the Schering-Plough Corporation, Dr. Spiegel retired in 2009 as chief medical officer and senior vice president of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. He initially joined Schering-Plough as director of clinical research for oncology and rose to hold various positions including senior director of clinical research for oncology and anti-infectives, vice president of clinical research and senior vice president of worldwide clinical research. Prior to Schering-Plough, Dr. Spiegel held academic positions at the National Cancer Institute and New York University Cancer Center. Following a residency in internal medicine, he completed a fellowship in medical oncology at the National Cancer Institute. He currently is an adjunct assistant professor at New York University Medical Center. Dr. Spiegel holds an M.D. from the University of Pennsylvania and a B.A. from Yale University. . . .
The talent is now nearly completely scattered -- to the four winds.
No comments:
Post a Comment